MedTrace Logo

The DRAGON 2 Trial

NCT05428735 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 348

Last updated 2024-11-01

No results posted yet for this study

Summary

In the randomized controlled DRAGON 2 trial study subjects will be randomized between two arms, PVE alone (control group) and PVE/HVE (interventional group).

Conditions

  • Colorectal Cancer Liver Metastases (CRLM)
  • Small Future Liver Remnant (FLR)

Interventions

PROCEDURE

Embolization

Portal Vein embolization with Glue by a transhepatic approach vs. PVE and Hepatic Vein Occlusion with Vascular plugs via a transjugular or transfemoral approach in the same session as the PVE procedure

Sponsors & Collaborators

  • Maastricht University

    lead OTHER

Principal Investigators

  • Ronald M. van Dam, PhD · Maastricht Universitair Medisch Centrum

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-04-01
Primary Completion
2026-06-30
Completion
2029-06-30

Countries

  • United States
  • Australia
  • Austria
  • Belgium
  • Canada
  • Italy
  • Netherlands
  • Sweden
  • Switzerland

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05428735 on ClinicalTrials.gov